David Ricks is a career Eli Lilly executive who joined the company in 1996 and became its CEO in January 2017 and chairman in June 2017. Under his leadership Lilly rode the success of tirzepatide -- sold as Mounjaro for type 2 diabetes and Zepbound for obesity -- to become one of the most valuable companies in the world, with a market capitalization that reached roughly $757 billion in 2025, the largest of any pharmaceutical company.
Lilly's power is the power of a near-essential medicine produced by a small number of firms. Tirzepatide and the broader GLP-1 class have reshaped how diabetes and obesity are treated, and demand has repeatedly outstripped supply. As chief executive, Ricks sets the prices, manufacturing build-out, and access terms for drugs that tens of millions of patients want, giving Lilly enormous leverage over public and private health budgets.
Ricks also sits at the center of the pharmaceutical industry's political relationships in Washington, chairing or serving on bodies such as the Business Roundtable and negotiating directly with administrations and Congress over drug pricing, making him both a corporate leader and an industry spokesman.
What they control
- Eli Lilly and Company: pricing, supply, and R&D strategy for the tirzepatide franchise (Mounjaro, Zepbound) and the broader diabetes/obesity pipeline
- A multibillion-dollar global manufacturing expansion that determines how quickly GLP-1 supply reaches patients
- Lilly's insulin portfolio, long a flashpoint in U.S. drug-pricing politics
- An extensive lobbying and government-affairs operation engaging Congress, CMS, and the White House on pricing policy
- A leadership voice in industry groups (Business Roundtable, PhRMA member company) shaping pharma's national posture
Key institutions & holdings
One of the world's most valuable drugmakers; maker of Mounjaro, Zepbound, and insulin brands.
CEO lobby representing major U.S. corporations.
Outside corporate board seat.
His undergraduate alma mater.
Key facts
- Became Lilly CEO in January 2017 and chairman in June 2017 after two decades at the company.
- Lilly's market capitalization reached about $757 billion in 2025, making it the most valuable pharmaceutical company in the world.
- Lilly guided 2026 revenue to roughly $82-85 billion, driven by tirzepatide.
- Q4 2025 Mounjaro revenue rose about 110% to $7.4 billion and Zepbound rose about 185% to $3.6 billion year over year.
- Ricks's reported 2024 total compensation was about $29.2 million.
- In March 2023 Lilly cut list prices of its most-prescribed insulins by 70% and capped patient out-of-pocket insulin costs at $35 a month.
Timeline
- 1996Joins Eli Lilly, beginning a long internal rise through its U.S. and international businesses.
- 2017Succeeds John Lechleiter as CEO (January) and becomes chairman of the board (June).
- 2022FDA approves Mounjaro (tirzepatide) for type 2 diabetes, launching Lilly's blockbuster franchise.
- 2023Lilly cuts insulin list prices 70% and caps out-of-pocket costs at $35; Ricks tells Sen. Bernie Sanders the company will not raise prices on existing insulins.
- 2023FDA approves Zepbound (tirzepatide) for chronic weight management.
- 2026Ricks publicly opposes the administration's push to codify 'most favored nation' international reference pricing into law.
Controversies
Insulin pricing history · 2010s-2023
Lilly was a central target of years of public and congressional criticism over high U.S. insulin list prices before its 2023 price cuts; critics noted the reductions followed sustained political pressure and a Medicare cap.
GLP-1 cost and access · 2023-2026
The high price and constrained supply of Mounjaro and Zepbound have strained insurers, employers, and Medicaid programs and left many patients unable to afford or obtain the drugs, raising questions about who benefits from a near-essential medicine.
Opposition to international reference pricing · 2025-2026
Ricks and Lilly opposed efforts to tie U.S. drug prices to lower prices paid abroad, arguing it would harm innovation; critics counter that U.S. patients subsidize lower prices elsewhere.
Network
- John LechleiterPredecessorFormer Lilly chairman and CEO whom Ricks succeeded in 2017.
- Daniel SkovronskyLieutenantLilly's chief scientific officer, central to the tirzepatide and pipeline strategy.
- Lilly EndowmentAffiliated institutionOne of the largest U.S. private foundations, tied historically to Lilly family stock.
- PhRMA / Business RoundtableIndustry alliesChannels through which Ricks advances pharma policy positions in Washington.
Why this matters
When a handful of companies control medicines that tens of millions of people depend on, a single CEO's choices about price, supply, and who gets access shape household budgets, insurance premiums, and public programs like Medicare and Medicaid. Lilly's dominance in diabetes and obesity drugs gives Ricks unusual leverage over what Americans pay for care and over the drug-pricing rules that govern the whole industry.